Inflammatory myofibroblastic tumor of the kidney with viral hepatitis B and trauma: A case report
- Authors:
- Published online on: October 1, 2013 https://doi.org/10.3892/ol.2013.1598
- Pages: 1741-1743
Abstract
Introduction
Inflammatory myofibroblastic tumor (IMT) is an uncommon tumor that was first described in the lung and has now been identified at multiple extrapulmonary anatomical sites (1). In the genito-urinary tract, IMT most commonly occurs in the bladder. However, a small series of renal IMT cases have been reported in the medical literature, to date (2–5). The etiology and pathogenesis of IMT remain uncertain; however, infection, vascular causes, autoimmune disorders and the anaplastic lymphoma kinase (ALK) gene have been proposed (7,8). The present study describes a case of a 48-year-old female with an IMT of the kidney, who was treated by radical nephrectomy and had a history of trauma to the left hypochondrium 13 years previously. The patient also had a history of hepatitis B for 20 years, which developed into hepatic cirrhosis, hypersplenism and coagulation disorders and may improve the understanding of the etiology and pathogenesis of renal IMT. Written informed consent was obtained from the patient.
Case report
A 48-year-old female visited the First Hospital, Jilin University (Jilin, China) for routine check-up for hepatitis B on July 19, 2012 and presented with no symptoms. The patient had a history of trauma to the left hypochondrium 13 years previously and a history of hepatitis B for 20 years. The latter developed into hepatic cirrhosis, hypersplenism and coagulation disorders. The physical and basic paraclinical examinations were normal. Blood tests revealed a leukocyte count of 2850/mm3, a hemoglobin count of 5.6 g/dl, a platelet count of 6700/mm3, a urine leukocyte count of 20.1/HPF and a urine erythrocyte count of 2.5/HPF. The thrombin time was 19.4 sec and the prothrombin time was 14.0 sec. The international normalized ratio was 1.21, the prothrombin ratio was 1.22 and the prothrombin activity was 69%. Clinical laboratory measurments revealed the following levels: Serum fibrinogen, 0.55 g/l; hepatitis B virus surface antigen (HBsAg), 197.260 IU/Ml; hepatitis B virus e antigen, 0.299S/CO; hepatitis B virus e antibody, 0.110S/CO; and hepatitis B virus core antibody, 18.210S/CO. An abdominal ultrasonography revealed a 1.4×1.4-cm-sized mass with an obscure boundary in the upper pole of the kidney, which protruded through the surface. The computed tomography (CT) scan revealed a 1.6×2.9×2.0-cm lesion in the upper pole of the kidney. The CT was slightly enhanced with contrast (Fig. 1). The magnetic resonance imaging revealed a heterogeneous mass measuring 2.6 cm, showing low intensity on the T1-weighted images and high intensity on the T2-weighted images, which was accompanied with hypointensity that surrounded the center of the lesion (Fig. 2). A radical nephrectomy was performed. The histopathological examination resulted in the lesion being diagnosed as an IMT, in which spindle cells were admixed with variable amounts of extracellular collagen, lymphocytes and plasma cells (Fig. 3). Immunostaining was positive for vimentin and focally positive for smooth muscle actin, desmin and Ki-67 (Fig. 4). There was no evidence of recurrence during a follow-up period of six months.
Discussion
IMT has been recognized as an inflammatory pseudotumor and has been considered to be a reparative post-inflammatory condition rather than a neoplastic process (6). However, rearrangements involving ALK have been documented in pulmonary and extrapulmonary IMTs, supporting the contention that IMT is a neoplasm (7). No definitive cause of the condition has been identified and the etiology is likely to be multifactorial, including infection, vascular causes and autoimmune disorders (8). However, the identification of the ALK gene fusion has allowed an improved recognition and understanding of the pathogenesis of IMT with regard to the genetic aspect (7). Granulomas and giant cells have been observed in the tumor tissue, suggesting that infection is associated with IMT (9). Numerous studies have indicated that IMT may be due to an intraparenchymal hemorrhage that is secondary to trauma or coagulopathy (10). Cotelingam and Jaffe have suggested that the initial event may be a focal parenchymal necrosis with hemorrhage (11). In the present study, the inflammatory reaction was suspected to have occurred as a consequence of the sedimentation of HBsAg or an antigen-antibody complex in the kidney. Furthermore, the intraparenchymal hemorrhage of the kidney may have been due to the left hypochondrium trauma history and the coagulation disorders that were caused by hepatic cirrhosis.
An IMT patient may be clinically asymptomatic or may present with flank pain, painless hematuria and ureteropelvic junction stenosis with hydronephrosis (12). Histologically, IMTs are characterized by a mix of inflammatory cells, including plasma cells, lymphocytes, eosinophils and bland spindle cells without nuclear atypia. The tumors may exhibit necrosis, hemorrhage, focal calcification and mitotic activity (6). Confirming a pre-operative diagnosis is difficult and the tumor may be misdiagnosed as renal cell carcinoma, as the symptoms and imaging findings are not specific and are particularly difficult to distinguish from renal cell carcinoma. Therefore, a nephrectomy is usually selected as a treatment strategy (13). Histological examination is of particular significance to obtain a clear diagnosis. However, an inadequate amount of tissue is often obtained by CT-guided fine needle aspiration. Therefore, the definitive diagnosis is often by histopathological examination of the resected specimen following surgery (14). IMT exhibits a good prognosis; Kapusta et al have reported a series of 12 cases of IMT of the kidney, of which the follow-up information was available in eight cases and ranged from 1 to 17 years, with no evidence of recurrence (12).
In summary, IMT of the kidney is extremely rare and the etiology and pathogenesis remain unclear. In the present case, the patient had a history of trauma of the left hypochondrium and a long-term history of hepatitis B, which developed into hepatic cirrhosis, hypersplenism and coagulation disorders. The subsequent conditions may have played a significant role in the development of IMT of the kidney in the present case, and may also be useful in increasing the understanding of the etiology and pathogenesis of IMT of the kidney.
Acknowledgements
The authors would like to thank the teachers at the Center of Urology and the support provided by the Departments of Radiology and Pathology at the First Hospital of Jilin University.
References
Coffin CM, Watterson J, Priest JR and Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 19:859–872. 1995. View Article : Google Scholar | |
Harik LR, Merino C, Coindre JM, Amin MB, Pedeutour F and Weiss SW: Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. Am J Surg Pathol. 30:787–794. 2006. View Article : Google Scholar : PubMed/NCBI | |
Harper L, Michel JL, Riviere JP, Alsawhi A and De Napoli-Cocci S: Inflammatory pseudotumor of the ureter. J Pediatr Surg. 40:597–599. 2005. View Article : Google Scholar : PubMed/NCBI | |
Larbcharoensub N, Chobpradit N, Kijvikai K and Chalermsanyakorn P: Primary renal inflammatory myofibroblastic tumor. Urol Int. 76:94–96. 2006. View Article : Google Scholar : PubMed/NCBI | |
Leroy X, Copin MC, Graziana JP, Wacrenier A and Gosselin B: Inflammatory pseudotumor of the renal pelvis: A report of 2 cases with clinicopathologic and immunohistochemical study. Arch Pathol Lab Med. 124:1209–1212. 2000.PubMed/NCBI | |
Gleason BC and Hornick JL: Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 61:428–437. 2008. View Article : Google Scholar : PubMed/NCBI | |
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E and Griffin CA: ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 14:569–576. 2001. View Article : Google Scholar : PubMed/NCBI | |
Gupta P, Dhingra KK, Singhal S, Mandal S, Khurana N and Saroha V: Inflammatory myofibroblastic tumour of the kidney with a papillary adenoma. Pathology. 42:193–196. 2010. View Article : Google Scholar : PubMed/NCBI | |
Oz Puyan F, Bilqi S, Unlu E, Yalcin O, Altaner S, Demir M and Cakir B: Inflammatory pseudotumour of the spleen with EBV positivity: report of a case. Eur J Haematol. 72:285–291. 2004.PubMed/NCBI | |
Horiuchi R, Uchida T, Kojima T and Shikata T: Inflammatory pseudotumor of the liver. Clinicopathologic study and review of the literature. Cancer. 65:1583–1590. 1990. View Article : Google Scholar : PubMed/NCBI | |
Cotelingam JD and Jaffe ES: Inflammatory pseudotumour of the spleen. Am J Surg Pathol. 8:375–380. 1984. View Article : Google Scholar | |
Kapusta LR, Weiss MA, Ramsay J, Lopez-Beltran A and Sriqley JR: Inflammatory myofibroblastic tumors of the kidney: a clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol. 27:658–666. 2003. View Article : Google Scholar : PubMed/NCBI | |
Ryu KH, Im CM, Kim MK, Kwon D, Park K, Ryu SB and Choi C: Inflammatory myofibroblastic tumor of the kidney misdiagnosed as renal cell carcinoma. J Korean Med Sci. 25:330–332. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bell ND, Gavras JN, Donnell CA and Rodning CB: Renal inflammatory pseudotumour. South Med J. 91:1050–1053. 1998. View Article : Google Scholar : PubMed/NCBI |